Research view
Switch to patient viewMyelodysplastic syndromes: trials that stopped early
Trials on Myelodysplastic syndromes that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
86 stopped trials give a reason in the registry, latest registry update first.
Suspended
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Reason given in the registry “Enrollment on hold pending amendment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.
- Phase
- Phase 1
- Run by
- University of Chicago
- Registry record
- NCT02333162
Terminated
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Reason given in the registry “Slow/low Enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Inmune Bio, Inc.
- Registry record
- NCT05933070
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Reason given in the registry “Development discontinued”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Mar 2026.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- Shattuck Labs, Inc.
- Registry record
- NCT05275439
Withdrawn
Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)
Reason given in the registry “Abandonment of the study project”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2026.
- Ended
- Jul 2024
- Run by
- Assistance Publique - Hôpitaux de Paris
- Registry record
- NCT04953312
Terminated
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2026.
- Ended
- Mar 2026
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT03404193
Terminated
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Drug supply issues”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Mar 2026.
- Ended
- May 2025
- Phase
- Phase 1
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT03772925
Withdrawn
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Reason given in the registry “Change in Study Design”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Ossium Health, Inc.
- Registry record
- NCT05170828
Withdrawn
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Reason given in the registry “Drug Source Request”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2026.
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06284460
Terminated
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2026.
- Ended
- Feb 2026
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04160052
Terminated
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Reason given in the registry “As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Jan 2026.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- NextCure, Inc.
- Registry record
- NCT05787496
Terminated
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Reason given in the registry “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jan 2026.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT03946670
Terminated
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Reason given in the registry “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jan 2026.
- Ended
- Oct 2024
- Phase
- Phase 3
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04266301
Terminated
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Reason given in the registry “Drug company withdrew support.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Dec 2025.
- Ended
- Mar 2025
- Phase
- Phase 1/2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT05918055
Terminated
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Reason given in the registry “Slow enrolment”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2025.
- Ended
- Oct 2025
- Phase
- Phase 1
- Run by
- Kahr Medical
- Registry record
- NCT04937166
Terminated
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Reason given in the registry “The study terminated early because the company was longer providing the investigational product.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2025.
- Ended
- Sept 2024
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04874194
Terminated
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
Reason given in the registry “Strategic Business Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- Incyte Corporation
- Registry record
- NCT04582539
Terminated
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Reason given in the registry “Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.
- Ended
- Sept 2024
- Phase
- Phase 2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04878432
Terminated
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Reason given in the registry “Business reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04810611
Terminated
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT03940352
Terminated
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
Reason given in the registry “The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2025.
- Ended
- Jul 2025
- Phase
- Phase 2
- Run by
- TC Biopharm
- Registry record
- NCT05358808
Terminated
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Reason given in the registry “Lack of Funding”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- Vor Biopharma
- Registry record
- NCT04849910
Terminated
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Reason given in the registry “Sponsor decision, unrelated to safety”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Amgen
- Registry record
- NCT05209152
Terminated
Connect® Myeloid Disease Registry
Reason given in the registry “Business objectives have changed”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.
- Ended
- Oct 2024
- Run by
- Celgene
- Registry record
- NCT01688011
Terminated
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Reason given in the registry “Trial terminated because of lack of efficacy in the short term acute phase.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2025.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Celgene
- Registry record
- NCT02848001
Withdrawn
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
Reason given in the registry “cprmc withdrawn”
Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06572631
Terminated
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Reason given in the registry “supporting/funding source decided to de-prioritize and stop development of DS-1594”
Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.
- Ended
- Nov 2023
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04752163
Terminated
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
Reason given in the registry “Company Development strategy adjustment\]”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Apr 2025.
- Ended
- Apr 2024
- Phase
- Phase 3
- Run by
- TJ Biopharma Co., Ltd.
- Registry record
- NCT05709093
Withdrawn
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
Reason given in the registry “Study disapproved by internal scientific review committee on re-review; study will no longer move forward”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Apr 2025.
- Phase
- Phase 2
- Run by
- University of Florida
- Registry record
- NCT05766514
Terminated
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
Reason given in the registry “Interim analysis determined that study reached a safety stopping rule”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Apr 2025.
- Ended
- May 2024
- Phase
- Phase 3
- Run by
- University of Florida
- Registry record
- NCT03016130
Terminated
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
Reason given in the registry “The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Mar 2025.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- GlaxoSmithKline
- Registry record
- NCT05424380
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.